Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub-/suprathreshold doses of L-Dopa upon motor behaviour of MPTP-treated mice

Journal of Neural Transmission

Volumn 106, Issue 9-10, 1999, Pages 889-909

  Fredriksson, A ^a   Palomo, T ^b   Archer, T ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Anticonvulsive agents; C57 BL 6 mice; Co administration; Dopamine; FCE 26743; L Deprenyl; L Dopa; Lamotrigine; Motor activity; MPTP; Parkinsonism; Phenytoin; Restoration; Subthreshold dose; Suprathreshold dose; Synergism

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTICONVULSIVE AGENT; DOPAMINE; LAMOTRIGINE; LEVODOPA; PHENYTOIN; SELEGILINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; LOCOMOTION; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTICONVULSANTS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; LEVODOPA; LOCOMOTION; MALE; MICE; MICE, INBRED C57BL; PARKINSON DISEASE;

EID: 0032744908     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050209     Document Type: Article

References (55)

1. Agarwal JC, Nath C, Gupta GP, Bhargava KP, Shanker K (1981) Anti-Parkinsonian and anticonvulsant activity of some silyl substituted dopamine derivatives. Pharmacol Res Comm 13; 937-947
2. Archer T, Fredriksson A, Jonsson G, Lewander T, Mohammed AK, Ross SB, Söderberg U (1986) Central noradrenaline depletion antagonizes aspects of d-amphetamine-induced hyperactivity in the rat. Psychopharmacology (Berl) 88: 141-146
3. Archer T, Bassen M, Peters D, Luthman J, Fredriksson A (1996) Dopaminergic-glutamatergic balance in the forebrain: functional studies of movement disorders in rats and mice. In: Beninger RJ, Palomo T, Archer T (eds) Dopamine disease states. Madrid University Press, Madrid, pp 117-154
4. Archer T, Fredriksson A (1999) Effects of acute/chronic, subthreshold/threshold doses of L-Dopa in MPTP-treated mice. I. Influence of competitive and noncompetitive NMDA antagonists. In: Palomo T, Beninger RJ, Archer T (eds) Interactive monoaminergic disorders. Editorial Sintesis, Madrid, pp 573-606
5. Azzaro AJ, Gutrecht JA (1975) Characteristics of the inhibitory action of diphenylhydantoin on brain monoamine oxidase. Neurology 25: 378-383
6. Bergmann KJ, Limongi JC, Lowe YH, Mendoza MR, Yahr MD (1984) Potentiation of the "dopa" effect in parkinsonism by a direct GABA receptor agonist [letter]. Lancet i: 559
7. Björk L, Cornfield LJ, Nelson DL, Hillver S-E, Andén N-E, Lewander T, Hacksell U (1991) Pharmacology of the novel 5-hydroxytryptamine 1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects. J Pharmacol Exp Ther 258: 58-65
8. Carey RJ (1991) Chronic L-Dopa treatment in the unilateral 6-OHDA rat: evidence for behavioural sensitization and biochemical tolerance. Brain Res 568: 205-214
9. Chow ML, Hendley CD (1959) Effect of monoamine inhibitors on experimental convulsions. Fed Proc 18: 376
10. Colombo M, Strolin Benedetti M, Bonsignori A, Cocchiara G, Roneucci R, Dostert P (1990) MAO activity, metabolism and anticonvulsant activity of milacemide in rats and mice. J Neural Transm 32 [Suppl]: 123-129
11. Dostert P, Strolin Benedetti M, Tipton KF (1991) New anticonvulsants with selective MAO-B inhibitory activity. Eur J Neuropharm 1: 317-319
12. Ebert U, Löscher W (1999) Monoamine interactions in animal models of epilepsy. In: Palomo T, Beninger RJ, Archer T (eds) Interactive monoaminergic basis of brain disorders. Editorial Sintesis, Madrid, pp 555-572
13. Engber TM, Papa SM, Boldry RC, Chase TN (1994) NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 5; 2586-2588
14. Fredriksson A, Archer T (1994) MPTP-induced behavioural and biochemical deficits: a paramatric analysis. J Neural Transm 7: 123-132
15. Fredriksson A, Archer T (1995) Synergistic interactions betseen COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice. J Neural Transm 102: 19-34
16. Fredriksson A, Plaznik A, Sundström E, Jonsson G, Archer T (1990) MPTP-induced hypoactivity in mice: reversal by L-dopa. Pharmacol Toxicol 67: 295-301
17. Fredriksson A, Gentsch C, Archer T (1994a) Synergistic interactions between NMDA-antagonists and L-Dopa on activity in MPTP-treated mice. J Neural Transm [Gen Sect] 97: 197-209
18. Fredriksson A, Gentsch C, Archer T (1994b) Effect of the competitive NMDA antagonist, CGP 40116, and a low dose of L-Dopa on the motor activity deficit of MPTP-treated mice. Behav Pharmacol 5: 599-606
19. Fredriksson A, Eriksson P, Archer T (1997) MPTP-induced deficits in motor activity: neuroprotective effects of the spintrapping agent, a-phenyl-tert-butyl-nitrone (PBN). J Neural Transm 104: 579-592
20. Fredriksson A, Palomo T, Chase T, Archer T (1999) Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists. J Neural Transm 106: 283-300
21. Goa KL, Ross SR, Chrisp P (1993) Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 46: 152-176
22. Greenamyre JT, Eller RV, Zhang Z, Ovadia A, Kurlan R, Gash DM (1994) Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 35: 655-661
23. Hadfield MG (1972) Uptake and binding of catecholamines. Effect of diphenylhydantoin and a new mechanism of action. Arch Neurol 26: 78-83
24. Heikkila RE, Sieber B-A, Manzino L, Sonsalla PK (1989) Some features of the nigrostiatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) in the mouse. Mol Chem Neuropathol 10: 171-183
25. Jones-Humble SA, Morgan PF, Cooper BR (1993) The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 Black mice in the MPTP animal model of Parkinson's disease. Life Sci 54: 245-252
26. Kaur S, Starr M (1996) Motor effects of lamotrigine in naive and dopamine-depleted mice. Eur J Pharmacol 304: 1-6
27. Kirk RE (1995) Experimental design. Procedures in behavioural science. Brooks/Cole Inc, Belmont CA
28. Kretschmer BD (1994) Felbamate, ananti-convulsive drug, has anti-parkinsonian potential in rats. Neurosci Lett 179: 115-118
29. Lamb RJ, Leach MJ, Miller AA, Wheatley PL (1985) Anticonvulsant profile in mice of lamotrigine, a novel anticonvulsant. Br J Pharmacol 85: 366P
30. Langston JW (1985) MPTP neurotoxicity: an overview and characterisation of phases of toxicity. Life Sci 36: 201-206
31. Löscher W (1985) Influence of pharmacological manipulation of inhibitory and excitatory neurotransmitter systems on seizure behaviour in the mongolian gerbil. J Pharmacol Exp Ther 233: 204-213
32. Löscher W, Honack D (1995) Anticonvulsant and antieleptogenic effect of L-Deprenyl (Selegiline) in the kindling model of epilepsy. J Pharmacol Exp Ther 274: 307-314
33. Löscher W, Lehmann H (1996) 1-Deprenyl (Selegiline) exerts anticonvulsant effects against different seizure types in mice. J Pharmacol Exp Ther 277: 1410-1417
34. Maj R, Antongiovanni V, Bonsignori A, Breda M, Dostert P, Fariello RG, McArthur RA, Varasi M, Bianchetti A (1993) Anticonvulsant profile of benzylamino-propranamide derivatives in mice and rats. Focus on Epilepsy II, International Conference, Whistler, Canada (Abstract)
35. Melamed E, Martinovits G, Pikarsky E, Rosenthal J, Uzzan A (1986) Diphenylhydantoin and phenobarbital suppresses the dopaminergic neurotoxicity of MPTP in mice. Eur J Pharmacol 128: 255-257
36. Meldrum BS (1994) The role of glutamate in epilepsy and other CNS disorders. Neurology 44: S14-S23
37. Merritt HH, Putnam TJ (1938) A new series of anticonvulsant drugs tested by experiments in animals. Arch Neurol Psychiat 39: 1003-1015
38. Miller AA, Wheatley P, Sawyer DA, Baxter MG, Roth B (1986) Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. 1. Anticonvulsant profile in mice and rats. Epilepsia 27: 483-489
39. O'Brien EM, Tipton KF, Meroni M, Dostert P (1994) Inhibition of monoamine oxidase by clorgyline analogues. J Neural Transm 41 [Suppl]: 295-305
40. Olson WL, Gruenthal M, Mueller ME, Olson WH (1997) Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. Am J Med 102: 60-66
41. Palmer GC, Cregan EF, Borrelli AR, Willett F (1995) Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Ann NY Acad Sci 765: 236-247
42. Prockop DJ, Shore PA, Brodie BB (1959) An anticonvulsant effect of monoamine oxidase inhibitors. Experientia 15: 145-147
43. Ramsay RE, Wilder BJ, Berger JR, Bruni J (1983) A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology 33: 904-910
44. Rho JM, Donevan SD, Rogawski MA (1994) Mechanism of action of anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and γ-aminobutyric acid A receptors. Ann Neurol 35: 229-234
45. Rouillard C, Bédard P, Falardeau P, DiPaolo T (1987) Behavioural and biochemical evidence for a different effect of repeated administration of L-Dopa and bromocriptine on denervated versus non-denervated striatal dopamine receptors. Neuropharmacology 26: 187-193
46. Silverman PB (1992) Sensitization, response fluctuation and long-term effect of SKF-82958 and bromocriptine in the hemi-parkinsonian rat. Eur J Pharmacol 229: 235-240
47. Shinotoh H, Vingerhoets FJ, Lee CS, Uitti RJ, Schulzer M, Calne DB, Tsui J (1997) Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study. Neurology 48: 1282-1285
48. Sonsalla PK, Heikkila RE (1986) The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol 129: 339-345
49. Strolin Benedetti M, Marrari P, Colombo M, Castelli MG, Arand M, Oesch F, Dostert P (1994) The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats. J Pharm Pharmacol 46: 814-819
50. Sundström E, Fredriksson A, Archer T (1990) Chronic neurochemical and behavioural changes in MPTP-lesioned C57 BL/6 mice: a model for Parkinson's disease. Brain Res 528: 181-188
51. Wallace SJ (1994) Lamotrigine - a clinical overview. Seizure 3: 47-51
52. Weihmüller FB, Hadjiconstantinou M, Bruno JP (1989) Dissociation between the biochemical and behavioural recovery in MPTP-treated mice. Pharmacol Biochem Behav 34: 113-117
53. Wheatley P, Miller AA (1989) Effects of lamotrigine on electrically induced after discharge in aneasthetised rat, dog and marmoset. Epilepsia 30: 34-40
54. Ye Liu Y, Yu H, Mohell N, Nordvall G, Lewander T, Hacksell U (1995) Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin. Mixed 5-HT1A-receptor agonists and dopamine-D2-receptor antagonists. J Med Chem 38: 150-160
55. Zipp F, Baas H, Fischer PA (1993) Lamotrigine - antiparkinsonian activity by blockade of glutamate release? J Neural Transm [P-D Sect] 5: 67-75